FormDSignal
47

Ensho Therapeutics raises $15.6M in biotech funding round

Company raise · Raising · WOODCLIFF LAKE, NJ · Form D filed 2026-10-15

Ensho Therapeutics, a Delaware biotech corporation incorporated in 2024, is raising $15.6M under Regulation D exemption 6(b). The company has sold $7.28M to 7 investors so far and is seeking an additional $8.32M.

$10M+ raiseoperating_company

Why now — by persona

  • Executive & technical recruiting:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • B2B software & services sales:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • Commercial banking / treasury:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • D&O and management-liability insurance:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • Outsourced accounting / CFO:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock

People on the filing

Danielle FryExecutive Officer
Arash RassoulpourDirector
Carlos SolorzanoDirector
Eric PhamDirector
Gerhard HagnDirector
Neena Bitritto-GargDirector
Tariq KassumDirector

Signed by Danielle Fry, Chief Legal Officer & Chief Operating Officer.

Filing contact

The issuer's phone number and address from the filing are shown to subscribers. See plans, or read it on EDGAR.

Other filings by this issuer